News | February 07, 2022
India grants Emergency Use Authorisation to Sputnik Light
This is the ninth Covid-19 vaccine approved in India
This is the ninth Covid-19 vaccine approved in India
Highest safety and efficacy of Sputnik V confirmed during clinical trials and in real-world use in more than 60 countries around the world
Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination
The company has started manufacturing the Sputnik Light vaccine
Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations
The Lancet study said that Sputnik Light showed 78.6 to 83.7 per cent efficacy against Covid-19, significantly higher than most two-shot vaccines
The batch will be distributed in India through a partner of RDIF and Panacea Biotec - Dr. Reddy's Laboratories
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik
Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19
Subscribe To Our Newsletter & Stay Updated
